Filter Results
:
(509)
Show Results For
-
All HBS Web
(1,290)
- Faculty Publications (509)
Show Results For
-
All HBS Web
(1,290)
- Faculty Publications (509)
- May 2023 (Revised June 2023)
- Supplement
Novartis (B): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Care and Treatment;
Business Model;
Production;
Business Strategy;
Pharmaceutical Industry
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (B): Reimagining Medicine." Harvard Business School Supplement 723-444, May 2023. (Revised June 2023.)
- May 2023 (Revised June 2023)
- Supplement
Novartis (C): Reimagining Medicine
By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi
This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,...
View Details
Keywords:
Health Testing and Trials;
Health Care and Treatment;
Business Model;
Problems and Challenges;
Pharmaceutical Industry;
Switzerland
Casadesus-Masanell, Ramon, Claudio Feser, Karolin Frankenberger, and David Redaschi. "Novartis (C): Reimagining Medicine." Harvard Business School Supplement 723-445, May 2023. (Revised June 2023.)
- April 2023 (Revised January 2024)
- Background Note
Note on Healthcare in Ghana
By: Regina E. Herzlinger and Ben Creo
This note provides an overview of the healthcare system in Ghana. It discusses the public and private sector as well as traditional medical practice. It also discusses the country’s pharmaceutical industry. It is recommended as a companion to Professor Regina...
View Details
Keywords:
Africa;
Pharmaceutical Companies;
Pharmacy Benefit Manager;
Health Care;
Health Care Costs;
Health Care Delivery;
Health Care Entrepreneurship;
Telehealth;
Health Equity;
Governing Rules, Regulations, and Reforms;
Health Care and Treatment;
Business and Government Relations;
Pharmaceutical Industry;
Pharmaceutical Industry;
Ghana
Herzlinger, Regina E., and Ben Creo. "Note on Healthcare in Ghana." Harvard Business School Background Note 323-112, April 2023. (Revised January 2024.)
- April 2023
- Case
Elliott Management: Capital Allocation in Biopharma
By: Amitabh Chandra, Paul Clancy and Lauren Gunasti
The case explores the intersection of capital allocation and shareholder activism in the biopharmaceutical industry. As many biopharma companies face looming patent expirations for key medicines, the case asks the question of whether investing in R&D and M&A is an...
View Details
Keywords:
Finance;
Strategy;
Capital Allocation;
Biopharmaceutical Industry;
Shareholder Activism;
Investment Activism;
Resource Allocation;
Research and Development;
Business and Shareholder Relations;
Corporate Strategy;
Pharmaceutical Industry
Chandra, Amitabh, Paul Clancy, and Lauren Gunasti. "Elliott Management: Capital Allocation in Biopharma." Harvard Business School Case 623-045, April 2023.
- May 4, 2023
- Article
Falling Insulin Prices—What Just Happened?
By: Leemore S. Dafny
Recently, more than 100 years after insulin was developed, manufacturers announced price reductions for insulin products. Pressure to reduce prices had long been building, so why would they act now?
View Details
Keywords:
Price;
Health Care and Treatment;
Public Opinion;
Demand and Consumers;
Pharmaceutical Industry
Dafny, Leemore S. "Falling Insulin Prices—What Just Happened?" New England Journal of Medicine 388, no. 18 (May 4, 2023): 1636–1639.
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19....
View Details
- March 2023 (Revised March 2024)
- Case
The Purdue Pharma Bankruptcy: Settling the Opioid Crisis
By: Kristin Mugford, Carin-Isabel Knoop and Susan Pinckney
How to get to a fair outcome for claimants in the Purdue Pharma bankruptcy given its significant role in the U.S. opioid crisis.
View Details
Keywords:
Regulation;
Ethics;
Fairness;
Insolvency and Bankruptcy;
Government Legislation;
Courts and Trials;
Laws and Statutes;
Lawsuits and Litigation;
Legal Liability;
Crime and Corruption;
Negotiation Offer;
Negotiation Participants;
Negotiation Style;
Product Design;
Product Development;
Brands and Branding;
Marketing Strategy;
Trust;
Government and Politics;
Law;
Negotiation;
Operations;
Ownership;
Marketing;
Social Psychology;
Health Care and Treatment;
Pharmaceutical Industry;
United States
Mugford, Kristin, Carin-Isabel Knoop, and Susan Pinckney. "The Purdue Pharma Bankruptcy: Settling the Opioid Crisis." Harvard Business School Case 223-060, March 2023. (Revised March 2024.)
- March 2023
- Teaching Note
Hikma Pharmaceuticals Governance Journey
By: Suraj Srinivasan and Jonah Goldberg
Teaching Note for HBS Case No. 318108. The case opens with Said Darwazah, chairman and CEO of Hikma Pharmaceuticals, the multinational generics company, anticipating the company’s 2017 AGM and reflecting on changes made over the previous year to address concerns...
View Details
Keywords:
Jordan;
Emerging Market;
Private Sector;
For-profit Firms;
Boards Of Directors;
Pharmaceuticals;
Remuneration;
Shareholder Engagement;
Corporate Governance;
Governing and Advisory Boards;
Business and Shareholder Relations;
Executive Compensation;
Business Growth and Maturation;
Pharmaceutical Industry;
Jordan
- March 2023
- Case
Roche: ESG and Access to Healthcare
By: George Serafeim, Susanna Gallani and Benjamin Maletta
In May 2022, Roche Group, one of the largest healthcare companies in the world, hosted its first ESG investor event focused exclusively on its efforts to impact access to healthcare. While Roche had recently set an ambitious goal to double the number of patients that...
View Details
Keywords:
ESG (Environmental, Social, Governance) Performance;
Sustainable Finance;
Growth Strategy And Execution;
Sustainability Targets;
Impact Evaluation;
Healthcare Access;
Healthcare Innovation;
Healthcare Systems;
Healthcare Operations;
Finance;
Strategy;
Health Testing and Trials;
Health Care and Treatment;
Growth Management;
Measurement and Metrics;
Innovation Strategy;
Corporate Social Responsibility and Impact;
Pharmaceutical Industry;
Pharmaceutical Industry;
Switzerland;
North America;
Europe;
Asia;
Latin America;
Africa
Serafeim, George, Susanna Gallani, and Benjamin Maletta. "Roche: ESG and Access to Healthcare." Harvard Business School Case 123-075, March 2023.
- January–February 2023
- Article
Forecasting COVID-19 and Analyzing the Effect of Government Interventions
By: Michael Lingzhi Li, Hamza Tazi Bouardi, Omar Skali Lami, Thomas Trikalinos, Nikolaos Trichakis and Dimitris Bertsimas
We developed DELPHI, a novel epidemiological model for predicting detected cases and deaths in the prevaccination era of the COVID-19 pandemic. The model allows for underdetection of infections and effects of government interventions. We have applied DELPHI across more...
View Details
Keywords:
COVID-19 Pandemic;
Epidemics;
Analytics and Data Science;
Health Pandemics;
AI and Machine Learning;
Forecasting and Prediction
Li, Michael Lingzhi, Hamza Tazi Bouardi, Omar Skali Lami, Thomas Trikalinos, Nikolaos Trichakis, and Dimitris Bertsimas. "Forecasting COVID-19 and Analyzing the Effect of Government Interventions." Operations Research 71, no. 1 (January–February 2023): 184–201.
- January 2023 (Revised August 2023)
- Case
Veeva Systems and the Transformation to a Public Benefit Corporation
By: Ranjay Gulati and Allison M. Ciechanover
Peter Gassner, the co-founder and CEO of Veeva Systems, steered the company through rapid scaling from its launch in 2007 to 2022. Year after year, the company had exceeded expectations, with its market capitalization reaching $50 billion at its peak. By 2022, the...
View Details
- January 2023
- Teaching Note
The Opioid Settlement and Executive Pay at AmerisourceBergen
By: Suraj Srinivasan and Li-Kuan Ni
Teaching Note for HBS Case No 122-014. In 2020, AmerisourceBergen Corporation, a Fortune 50 company in the drug distribution industry, agreed to settle thousands of lawsuits filed nationwide against the company for its opioid distribution practices that critics alleged...
View Details
Keywords:
Opioids;
Shareholder Activism;
Investment Activism;
Corporate Accountability;
Corporate Governance;
Governance Compliance;
Governance Controls;
Executive Compensation;
Risk Management;
Corporate Social Responsibility and Impact;
Business and Shareholder Relations;
Business and Stakeholder Relations;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States;
West Virginia;
Tennessee;
Ohio;
Pennsylvania
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful...
View Details
Keywords:
Product Development;
Leadership;
Health Testing and Trials;
Research and Development;
Risk and Uncertainty;
Financial Condition;
Partners and Partnerships;
Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- December 2022
- Article
The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies
By: Pragya Kakani, Michael Chernew and Amitabh Chandra
Context: To what extent does pharmaceutical revenue growth depend on new medicines versus increasing prices for existing medicines? Moreover, does using list prices, as is commonly done, instead of prices net of confidential rebates offered by manufacturers, which are...
View Details
Kakani, Pragya, Michael Chernew, and Amitabh Chandra. "The Contribution of Price Growth to Pharmaceutical Revenue Growth in the United States: Evidence from Medicines Sold in Retail Pharmacies." Journal of Health Politics, Policy and Law 47, no. 6 (December 2022): 629–648.
- November 2022
- Case
The Battle Among Channels for Marketing Pharmaceuticals: UpScript, Pharmacy Benefit Managers, and Direct-to-Consumer Sales
By: Regina E. Herzlinger and Tiffany Farrell
Can an online, direct-to-consumer pharmacy both improve the quality and speed of care for patients who need branded drugs and stabilize profits for pharmaceutical manufacturers? UpScript, after years spent achieving legal and regulatory compliance and simultaneous...
View Details
Keywords:
DTC;
Internet and the Web;
Marketing Channels;
Customer Value and Value Chain;
Governing Rules, Regulations, and Reforms;
Competitive Strategy;
Service Delivery;
Growth and Development Strategy;
Pharmaceutical Industry;
Pharmaceutical Industry;
Pharmaceutical Industry
Herzlinger, Regina E., and Tiffany Farrell. "The Battle Among Channels for Marketing Pharmaceuticals: UpScript, Pharmacy Benefit Managers, and Direct-to-Consumer Sales." Harvard Business School Case 323-031, November 2022.
- November 2022 (Revised April 2024)
- Case
Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams
By: Debora L. Spar and Julia M. Comeau
In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At the time, there was little medication...
View Details
Keywords:
Pharmaceutical Companies;
Technological And Scientific Innovation;
Organ Donation;
Health Care and Treatment;
Health Disorders;
Innovation and Invention;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States;
District of Columbia
Spar, Debora L., and Julia M. Comeau. "Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams." Harvard Business School Case 323-039, November 2022. (Revised April 2024.)
- October 2022
- Case
Cost Plus Drugs
By: Alexander MacKay and James Barnett
In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies....
View Details
Keywords:
Business Ventures;
Decision Making;
Entrepreneurship;
Ethics;
Health;
Markets;
Social Enterprise;
Society;
Strategy;
Health Care and Treatment;
Business Divisions;
Factories, Labs, and Plants;
Pharmaceutical Industry;
Pharmaceutical Industry;
United States;
Texas
MacKay, Alexander, and James Barnett. "Cost Plus Drugs." Harvard Business School Case 723-362, October 2022.
- October 2022 (Revised January 2024)
- Case
mPharma: Scaling Access to Affordable Primary Care in Africa
By: Regina E. Herzlinger and Ben Creo
mPharma hopes to scale up to create the largest pan-African healthcare company ever to provide much-needed primary care in retail pharmacies; a reliable, fairly priced supply of drugs; and micro-insurance for drugs. They must prioritize launching a telemedicine...
View Details
Keywords:
Africa;
Pharmaceutical Companies;
Pharmacy Benefit Manager;
Health Care;
Health Care And Treatment;
Health Care Costs;
Health Care Delivery;
Health Care Entrepreneurship;
Telehealth;
Health Equity;
Corporate Strategy;
Social Entrepreneurship;
Equity;
Growth and Development Strategy;
Expansion;
Product Launch;
Customer Value and Value Chain;
Social Enterprise;
Multinational Firms and Management;
Pharmaceutical Industry;
Pharmaceutical Industry;
Africa
Herzlinger, Regina E., and Ben Creo. "mPharma: Scaling Access to Affordable Primary Care in Africa." Harvard Business School Case 323-033, October 2022. (Revised January 2024.)
- September 2022
- Article
Find and Replace: R&D Investment Following the Erosion of Existing Products
By: Joshua L. Krieger, Xuelin Li and Richard T. Thakor
How do innovative firms react when existing products experience negative shocks? We explore this question with detailed project-level data from drug development firms. Using FDA Public Health Advisories as idiosyncratic negative shocks to approved drugs, we first...
View Details
Keywords:
R&D Investments;
Drug Development;
Product Shocks;
M&A;
Biopharmaceutical Industry;
FDA;
System Shocks;
Research and Development;
Investment;
Decision Making;
Pharmaceutical Industry
Krieger, Joshua L., Xuelin Li, and Richard T. Thakor. "Find and Replace: R&D Investment Following the Erosion of Existing Products." Management Science 68, no. 9 (September 2022): 6552–6571.
- September 2022
- Article
Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities
By: Leemore Dafny, Christopher Ody and Teresa Rokos
The federal Anti-Kickback Statute prohibits biopharmaceutical manufacturers from directly covering Medicare enrollees’ out-of-pocket spending for the drugs they manufacture, but manufacturers may donate to independent patient assistance charities and earmark donations...
View Details
Keywords:
Cost Sharing;
Prescription Drugs;
Drug Spending;
Medicare;
Dual Eligibility;
Cost;
Health Care and Treatment;
Philanthropy and Charitable Giving;
Pharmaceutical Industry
Dafny, Leemore, Christopher Ody, and Teresa Rokos. "Giving a Buck or Making a Buck? Donations by Pharmaceutical Manufacturers to Independent Patient Assistance Charities." Health Affairs 41, no. 9 (September 2022).